A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results.

Find information on myelodysplastic syndrome here. Cancer can start any place in the body. Myelodysplastic syndromes , or MDS for short, are cancers that start in the bone marrow, the soft inner part ...

Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), ...

There are different types of MDS. It is important to get an accurate diagnosis to get the proper treatment for the type of MDS a person has. Some types, referred to as “low-risk MDS” progress slowly ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome. Study ...

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.

The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...